...$63 million. Existing investors Column Group and DCVC Bio...

...Myers Squibb Co. (NYSE:BMY).The project first drew the attention of seed investors MPM Capital and DCVC Bio...
...Michael JensenUniversity collaborators: Purdue UniversityCorporate partners: N/ANumber of employees: 38Funds raised: $61 millionInvestors: MPM Capital, DCVC Bio...

...MPM Capital (see “The Dynamics of Dyne”).DCVC closes latest bio fund at $350M DCVC has launched DCVC Bio...

...company experience. An undisclosed investor also co-led the round. Other series D investors included 8VC, DCVC Bio...
...N/A Number of employees: 40 Funds raised: About $300 million Investors: Lightspeed Venture Partners, 8VC, DCVC Bio...

...therapy proposed the offering early that day. Big data investor DCVC aiming for $275M fund DCVC Bio...
...Targets S1PR1 (S1P1; EDG1) - Sphingosin 1-phosphate receptor 1 BioCentury Staff Windtree Therapeutics Inc. Allogene Therapeutics Inc. Adaptimmune Therapeutics plc DCVC Bio KL4...

...all partnered -- through Phase II testing. New investor OrbiMed Advisors and existing investor DCVC Bio...

...A round. Ionis contributed $10 million in equity to lead the $17 million A-2 round. DCVC Bio...

...Novome’s engineered microbe platform attracted DCVC Bio to lead its $33 million series A because of the...

...AI platform-generated programs from Atomwise, which launched the JV last year with Velocity Pharmaceutical Development. DCVC Bio...
...of several veteran drug developers with the world’s most advanced AI small molecule discovery engine,” DCVC Bio’s...

...to sort through millions of compounds for those that send E3 ligases to therapeutic targets. DCVC Bio...